Home \ Antibodies \ Beta1 Integrin, Human, mAb BV7, FITC
FC in Huvec cells
Catalog # HM2033F

Beta1 Integrin, Human, mAb BV7, FITC

Please choose the quantity of items you wish to add to your cart…
Find distributor

The monoclonal antibody BV7 recognizes human ß1-integrin. Beta-1 integrin is a ubiquitously expressed ~89 kDa type I transmembrane protein functioning as receptor when heterodimerized with one alpha subunit. It belongs to the integrin beta chain family consisting of four different genes, encoding multiple β-integrins via alternative splicing. Ligand-recognition depends on the composition of the heterodimer: either collagen, fibronectin, VCAM1, laminin, cytotactin, osteopontin, epiligrin, thrombospondin and CSPG4 can bind to the integrin-complex. Beta-1 integrins recognize the sequence R-G-D in a wide array of ligands. Isoform beta-1B interferes with isoform beta-1A resulting in a dominant negative effect on cell adhesion and migration (in vitro). In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi’s sarcoma lesions. When associated with α7, β1-integrin regulates cell adhesion and laminin matrix deposition. BV7 is active on HT-29 colon carcinoma cells and on HCCP-2998 tumor cells. It is involved in promoting endothelial cell motility and angiogenesis. Furthermore, β1-integrin plays a mechanistic adhesive role during telophase, and is required for the successful completion of cytokinesis.
Upon activation integrins in general, including β1-integrin, are known to exhibit global structural rearrangements and exposure of ligand binding sites. β1-integrin modulation is of importance in tissue repair and regeneration. In cultured primary hippocampal neurons, astrocytes and tissues, cell surface expression of amyloid beta fibrils (key hallmark of Alzheimer’s disease) selectively co-localized with β1-integrin. Preincubation of cells with antibodies against β1-integrin, as well as α1-integrin, greatly enhanced amyloid beta-induced apoptosis, indicating a protective role for integrins in apoptosis.
The monoclonal antibody BV7 does not recognize α5β1 complex and not the cytoplasmic part of the β1-subunit. BV7 binds to several other tumor cells (MG3 osteosarcoma, A375 melanoma, MHCC-1410 and Lovo colon carcinoma) but does not affect adhesion to endothelial cells.

Flow cytometry, Functional studies, Immuno assays, Immuno precipitation, Western blot

Application Notes
FC: Antibody BV7 stains the extracellular domain of beta-1 integrin. HUVEC cells were fixed in 4% paraformaldehyde before staining. Mouse IgG1 isotype was used as negative.
FS: Antibody BV7 functions as an inhibiting antibody. The antibody was functionally tested by adhesion assay (ref 1), chemotaxis (ref 2), patch clamp analysis (ref 3) and neurotoxicity induced apoptosis (ref 4).

Dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.

Positive Control
HT-29 colon carcinoma, Endothelial cells

Product type
Monoclonal antibodies
100 µg, 20 µg
0.2 ml (100 μg/ml) 0.2 μm filtered protein G purified FITC conjugated antibody solution in PBS, containing 1% bovine serum albumin and 0.02% sodium azide.
Human umbilical vein EC
Mouse IgG1
Integrin beta-1, Fibronectin receptor subunit beta, Glycoprotein IIa, GPIIA, VLA-4 subunit beta, CD29<br> - Gene name: ITGB1, FNRB, MDF2, MSK12
Storage and stability
Product should be stored at 4 °C. Under recommended storage conditions, product is stable for at least one year.
For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.
Autoimmunity, Neurological disorders

Calculate your ELISA data easily

With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.

Latest Hycult Biotech news

  • New Human Complement Pathway Assays
    We are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
  • Navigating the pitfalls in complement analysis
    Our colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
  • NEW Human C3d ELISA
    We are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA
Contact us